Results 101 to 110 of about 11,293 (160)

Transgenic Monkey Model of the Polyglutamine Diseases Recapitulating Progressive Neurological Symptoms. [PDF]

eNeuro, 2017
Tomioka I, Ishibashi H, Minakawa EN, Motohashi HH, Takayama O, Saito Y, Popiel HA, Puentes S, Owari K, Nakatani T, Nogami N, Yamamoto K, Noguchi S, Yonekawa T, Tanaka Y, Fujita N, Suzuki H, Kikuchi H, Aizawa S, Nagano S, Yamada D, Nishino I, Ichinohe N, Wada K, Kohsaka S, Nagai Y, Seki K.   +26 more
europepmc   +1 more source

A brain-targeting lipidated peptide for neutralizing RNA-mediated toxicity in Polyglutamine Diseases. [PDF]

Sci Rep, 2017
Zhang Q, Yang M, Sørensen KK, Madsen CS, Boesen JT, An Y, Peng SH, Wei Y, Wang Q, Jensen KJ, Zuo Z, Chan HYE, Ngo JCK.   +12 more
europepmc   +1 more source

Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies. [PDF]

Front Mol Neurosci, 2018
Xiang C, Zhang S, Dong X, Ma S, Cong S.
europepmc   +1 more source

Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases. [PDF]

Front Mol Neurosci, 2017
Sambataro F, Pennuto M.
europepmc   +1 more source

Nanoscale studies link amyloid maturity with polyglutamine diseases onset. [PDF]

Sci Rep, 2016
Ruggeri FS, Vieweg S, Cendrowska U, Longo G, Chiki A, Lashuel HA, Dietler G.   +6 more
europepmc   +1 more source

Uncoupling the Trade-Off between Somatic Proteostasis and Reproduction in Caenorhabditis elegans Models of Polyglutamine Diseases. [PDF]

Front Mol Neurosci, 2017
Shemesh N, Shai N, Meshnik L, Katalan R, Ben-Zvi A.   +4 more
europepmc   +1 more source

Aggregation formation in the polyglutamine diseases: protection at a cost? [PDF]

Mol Cells, 2013
Todd TW, Lim J.
europepmc   +1 more source

DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. [PDF]

Ann Neurol, 2016
Bettencourt C, Hensman-Moss D, Flower M, Wiethoff S, Brice A, Goizet C, Stevanin G, Koutsis G, Karadima G, Panas M, Yescas-Gómez P, García-Velázquez LE, Alonso-Vilatela ME, Lima M, Raposo M, Traynor B, Sweeney M, Wood N, Giunti P, SPATAX Network, Durr A, Holmans P, Houlden H, Tabrizi SJ, Jones L.   +24 more
europepmc   +1 more source

Oligonucleotide-based strategies to combat polyglutamine diseases. [PDF]

Nucleic Acids Res, 2014
Fiszer A, Krzyzosiak WJ.
europepmc   +1 more source

RNA-mediated pathogenic mechanisms in polyglutamine diseases and amyotrophic lateral sclerosis. [PDF]

Front Cell Neurosci, 2014
Chan HY.
europepmc   +1 more source